Abstract
We have carried out a clinical evaluation of the effectiveness of meropenem (MEPM), a new carbapenem antibiotic, for respiratory infections.
Nine patients, 6 with pneumonia and 3 with bronchiectasis, were treated with 500 mg or 1000 mg of MEPM given once or twice a day intravenously.
The clinical response was excellent in 3 cases, good in 5 and fair in 1, and the efficacy rate (above good response) was 88.9%.
No patients showed any subjective or objective side effects. GOT and GPT levels increased slightly in two patients during treatment but returned to normal during or after the termination of treatment.
From the above results, we conclude that MEPM is a useful option for the treatment of mild to severe respiratory infections.
